PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS Real world ischaemic event reduction with PCSK9i mAbs Inclisiran role in plaque stabilisation Discontinuing PCSK9i leads to increased MACE V-MONO trial of inclisiran monotherapy meets primary endpoints

ALN-PCS

Phase I study

Trial Phase I trial, reformulated ALN-PCS Aim To investigate the safety, tolerability and LDL cholesterol lowering of ALN-PCSsc (subcutaneous injection) Study design Part A (single dose): Randomised 3:1, Single blind, Placebo controlled designPart B (multi dose): Randomised 6:2, Single blind, Placebo controlled, On or off…

Posted on 11 July 2016 | Posted in ALN-PCS

ALN-PCSsc data suggest 6-month dosing

There was more news from the Phase I trial of ALN-PCSsc, an investigational RNAi therapeutic targeting PCSK9, presented at the last Latebreaker Clinical Trials session. Following initial results, presented at the European Society of Cardiology Congress, London, data reported at the American Heart Association Scientific…

Posted on 12 November 2015 | Posted in News, ALN-PCS, AHA Scientific Sessions 2015

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters